For research use only. This article covers the receptor pharmacology that researchers reference when they describe PT-141, also called bremelanotide. The compound also happens to be the active ingredient in Vyleesi, an FDA-approved pharmaceutical product — but research-grade bremelanotide sold for in-vitro work is not equivalent to that pharmaceutical product. Everything below is chemistry and receptor biology. Nothing here is guidance for use in people or animals.
Bremelanotide shows up everywhere in melanocortin-pharmacology literature, but the phrase that usually follows it — "a melanocortin receptor agonist" — almost never gets unpacked plainly. So what is a melanocortin receptor? There are five of them. Only some matter to PT-141. And the way they transmit signals inside a cell is a small but specific corner of G-protein-coupled receptor (GPCR) biology. The sections below walk through that chemistry the way you'd want a curious colleague to walk you through it: what the molecule is, what the receptor family is, where PT-141 lands on it, how those receptors signal, and which tissues actually carry them.
Bremelanotide's chemical anatomy
Short version: PT-141 is a cyclic seven-residue peptide built around the same active fragment as the natural hormone alpha-melanocyte-stimulating hormone (alpha-MSH).
Its formal sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, and the chemistry registry assigns it CAS number 189691-06-3, molecular formula C50H68N14O10, and molar mass 1025.18 g/mol. The "cyclo" in the middle of that sequence is the structural anchor: an amide bridge between aspartate-5 and lysine-10 ties the linear chain into a ring. Cyclisation buys you two things. First, the molecule becomes resistant to proteases that would otherwise hydrolyse a linear seven-residue peptide within minutes. Second, the binding face locks into a productive shape, so less of the molecule's energy goes into searching for the right conformation.
Inside that ring, four residues do the actual receptor-recognition work: His-D-Phe-Arg-Trp. This tetrad is the conserved pharmacophore — the same one shared by alpha-MSH itself, by NDP-alpha-MSH, by melanotan-II, and by bremelanotide. A 2007 review of melanocortin receptors and melanotropic peptides traces why the D-amino-acid substitution at position 7 (D-Phe instead of L-Phe) stabilises the active-state conformation when the peptide docks into an MC receptor. Native alpha-MSH is a 13-residue linear peptide; bremelanotide takes that core, trims it to seven residues, cyclises it, and protects it.
If you want context on how peptides at this size class are physically produced — solid-phase synthesis, side-chain protection, lyophilization — see our companion piece on how synthetic peptides are actually made. Bremelanotide sits in the same chemical neighbourhood as Selank, another cyclic heptapeptide, though the two molecules engage entirely different receptor systems.
The melanocortin receptor family at a glance
"Melanocortin receptor" isn't one protein. It's a family of five related cell-surface proteins, conventionally numbered MC1R through MC5R, all derived from the same evolutionary root and all responsive to peptides produced from the POMC (pro-opiomelanocortin) precursor.
Each of the five sits in a different functional context:
- MC1R — expressed primarily on melanocytes and keratinocytes in skin. Activation by alpha-MSH or its analogues drives eumelanin production. This is the receptor most often invoked when bremelanotide is associated with cutaneous pigmentation changes in research contexts.
- MC2R — restricted to the adrenal cortex. Its native ligand is ACTH, not alpha-MSH, and PT-141 is essentially silent here. It's the only family member that bremelanotide doesn't meaningfully engage.
- MC3R — found in the central nervous system, with the densest expression in the arcuate nucleus and ventromedial hypothalamus, where it participates in the circuitry that regulates energy homeostasis.
- MC4R — the most broadly expressed CNS member, with populations in the paraventricular nucleus, the lateral hypothalamic area, and the medial preoptic area. This is the receptor most often discussed in pharmacology papers about bremelanotide's central actions.
- MC5R — concentrated in exocrine glands, sebocytes, and certain immune cells.
All five belong to the same architectural class: class A (rhodopsin-like) G-protein-coupled receptors. Each is a seven-transmembrane protein that translates an extracellular peptide-binding event into an intracellular signalling cascade. They share a common shape, a common pharmacophore preference, and a common downstream toolkit. What differentiates them is tissue distribution, accessory proteins, and which intracellular pathways they couple to most strongly.
Where PT-141 lands on that family
Short version: bremelanotide is a non-selective agonist. It engages four of the five family members with measurable potency, and the order in which it prefers them is well documented.
The prescribing information for Vyleesi, the FDA-approved pharmaceutical formulation of bremelanotide, lists the potency rank order as MC1R > MC4R > MC3R > MC5R > MC2R. That's regulatory-grade pharmacology language — the agency is reporting the rank order published in the underlying biology, not endorsing any particular interpretation of it.
A separate pharmacology summary from ScienceDirect's bremelanotide overview frames the same molecule primarily as an MC3R and MC4R agonist, with higher affinity for MC4R than for MC3R. The two descriptions look contradictory at first read; they're reconcilable. Rank-order of potency at one set of receptors does not mean equal pharmacological "importance" of each one in every assay. Different cell systems, different second messengers measured, and different concentration ranges all shift the apparent picture. The framing researchers use depends on what they are trying to explain — pigmentation work tends to lead with MC1R, central-nervous-system work tends to lead with MC4R.
This is where receptor selectivity becomes a real chemistry question rather than a marketing one. Compare bremelanotide to setmelanotide, a substantially MC4R-selective analogue, or to afamelanotide, whose MC1R activity sits at the centre of its pharmacology. Non-selective ligands like bremelanotide engage the whole family at meaningful potency; selective ligands target one receptor more cleanly. For a contrasting example of selective receptor engagement, see our explainer on selective receptor agonists like ipamorelin — a non-melanocortin compound, but a clean illustration of the structural-versus-functional-selectivity distinction.
One thing worth being precise about: discussing how a molecule binds a receptor family is a chemistry statement. It isn't an outcome statement about anything that happens to a person.
How melanocortin receptors signal once they're activated
The canonical path is the same one every class-A GPCR follows. A ligand docks into the extracellular orthosteric pocket. Transmembrane helix 6 shifts outward. The cytoplasmic face exposes a G-protein binding site. A heterotrimeric G-protein loaded with GDP exchanges that GDP for GTP. The activated alpha-subunit dissociates and acts on its downstream effector.
For MC4R, the primary effector is Gs — the stimulatory G-protein. The activated Gs alpha-subunit binds and activates adenylyl cyclase, which converts cytoplasmic ATP into cyclic adenosine monophosphate (cAMP). Elevated cAMP then activates protein kinase A (PKA), which phosphorylates a broad set of downstream targets. The 2024 review of melanocortin intracellular signalling describes this as the dominant MC4R pathway, with a secondary contribution from Gq, which activates phospholipase C-beta, generates IP3, and engages protein kinase C.
MC3R uses a partially overlapping toolkit. It also couples to Gs and raises cAMP. But it additionally couples to Gi — driving the ERK1/2 pathway through PI3K — and can elevate intracellular calcium. The mixed-coupling profile is part of why MC3R pharmacology is harder to read out cleanly than MC4R pharmacology.
A 2024 cryo-EM study, Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist, resolved the activated MC4R bound to a synthetic nanobody agonist at near-atomic detail. The orthosteric pocket sits between transmembrane helices 2, 3, 6, and 7, and it's roofed by extracellular loops 1 and 2 — and the His-Phe-Arg-Trp tetrad common to alpha-MSH-family peptides slots into a deep aromatic cleft inside it. That's the molecular reason the pharmacophore is conserved: every alpha-MSH analogue, including bremelanotide, has to occupy roughly the same volume of space in the same chemical neighbourhood to activate the receptor.
One more layer worth naming: MRAP1 and MRAP2, the melanocortin-2-receptor accessory proteins, were originally identified as the chaperones that escort MC2R to the cell surface. More recent work shows they also fine-tune the surface expression and signalling pharmacology of MC3R and MC4R. Pharmacology measured in a cell line that lacks the relevant MRAP isoform can look meaningfully different from pharmacology measured in tissue where MRAPs are abundant.
Where the receptors live in tissue
Receptor distribution drives what researchers actually care about. A receptor that binds a molecule but is barely expressed in any tissue of interest is a less interesting receptor for that programme — and the inverse is true.
For melanocortin receptors and PT-141, the relevant geography looks like this. MC1R sits on melanocytes and keratinocytes in skin; activation drives melanin production, and this is the receptor invoked when repeated exposure to bremelanotide is associated with cutaneous pigmentation observations in the literature. MC4R is broadly expressed across hypothalamic populations — paraventricular nucleus, lateral hypothalamic area, and medial preoptic area — and the neural-melanocortin-receptors review notes that the medial preoptic pool is the population most often cited in literature on sexual-response pharmacology. MC3R is more anatomically restricted, with the densest expression in the arcuate nucleus and ventromedial hypothalamus, both involved in feeding circuits. MC5R turns up most prominently in exocrine glands and sebocytes.
Two practical points fall out of this distribution map. First, the fact that one ligand can engage four receptors at meaningful potency does not mean it does four things equally — what each receptor does depends on where it's expressed and what its tissue partner proteins (G-proteins, MRAPs, regulators of G-protein signalling) are doing. Second, receptor-binding pharmacology measured in a transfected HEK293 cell line is one floor of evidence; tissue-level behaviour is another floor entirely. Bridging the two is most of the actual research effort in the melanocortin field.
Frequently asked questions
What is PT-141 chemically?
PT-141, also called bremelanotide, is a cyclic heptapeptide lactam with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It carries the CAS number 189691-06-3 and the molecular formula C50H68N14O10. Structurally it's an analogue of the natural hormone alpha-melanocyte-stimulating hormone (alpha-MSH), shortened to seven residues and stabilised by an internal Asp-Lys amide bridge that holds the binding face in a productive shape.
What does "melanocortin receptor" actually mean?
The phrase refers to a family of five related cell-surface proteins — MC1R, MC2R, MC3R, MC4R, and MC5R — that all bind peptide hormones derived from the POMC precursor. They're class-A G-protein-coupled receptors: each is a seven-transmembrane protein that activates an intracellular signalling cascade (most often through Gs and cAMP) when the right peptide docks into its extracellular pocket. The five family members differ mostly in where they're expressed in the body.
Which melanocortin receptors does PT-141 prefer?
Published pharmacology data, including the FDA prescribing information for the Vyleesi formulation of bremelanotide, list the rank order of potency as MC1R > MC4R > MC3R > MC5R, with essentially no activity at MC2R. In research-grade discussions the receptors that get the most attention are MC4R (because of its prominent CNS expression) and MC1R (because of its role in pigmentation), but PT-141 is technically a non-selective agonist of the family.
How is PT-141 different from melanotan-II?
Bremelanotide is the deaminated metabolite of melanotan-II. The two peptides share the same cyclic core and the same His-D-Phe-Arg-Trp pharmacophore. The chemical difference is at the C-terminus: bremelanotide carries a free carboxylate where melanotan-II carries an amide. That single modification is what Palatin Technologies patented and developed into the compound the FDA reviewed in 2019. Pharmacologically they're close relatives; structurally they're distinguishable, and they sit in different regulatory and supply contexts.
Closing the loop
"PT-141 binds melanocortin receptors" is a precise statement about a five-member GPCR family — not vague pharmacology. The interesting research questions aren't whether the molecule binds, but how its non-selective profile across MC1R, MC3R, MC4R, and MC5R intersects with each receptor's tissue distribution and downstream second-messenger biology. Structural biology has accelerated the field — cryo-EM structures of activated MC4R are now public — and accessory-protein research is reshaping how the same receptor's pharmacology gets interpreted in different tissue contexts.
For readers who want a similar chemistry-first treatment of a different research peptide, see our companion explainer on TB-500's chemical structure and in-vitro research applications.
For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.
Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.